Malignant Pancreatic Neoplasm — Trials

Malignant Pancreatic Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

3,629 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 903
Recruiting: 504
Ph III recruiting: 46
Growth YoY: +21.9%
Industry share: 32%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.5%
Trials / 1,000 deaths: 18.3 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (516)

clinicaltrialsPublishedShowing 1–50 of 72 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07833241	Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC(ZSPAC-22)	not yet recruiting	Phase 2	56	Shanghai Zhongshan HospitalOTHER	1	Sep 22, 2026	clinicaltrials
NCT07831330	Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer	not yet recruiting	Phase 2	59	The First Affiliated Hospital with Nanjing Medical UniversityOTHER